??Effect of ondansetron in treatment of irritable bowel syndrome (IBS)

The effect of ondansetron in the treatment of patients with diarrhea dominant irritable bowel syndrome (IBS)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190703044084N2

Enrollment

100

Registered

2020-04-20

Start date

2019-06-27

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome with diarrhea. Irritable bowel syndrome with diarrhea

Interventions

Intervention 1: Intervention group: 50 patients treated by Imipramine (made by Abidi Pharma Compony) daily 25 mg and ondansetron (made by Abidi Pharma Compony) 4mg 3 times per day for up to 2 months.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with irritable bowel syndrome with diarrhea predominance based on Rome III criteria Age:Between 18-50 years

Exclusion criteria

Exclusion criteria: Pregnancy Lactation Dissatisfaction to be included in the study Any sign and symptom of inflammatory bowel disease Psychiatric drug use Drugs Interaction with ondansetron including: p450 enzyme system inducers (carbamazepine, phenobarbital, phenytoin, dexamethasone, rifampicin) p450 enzyme system inhibitors (clarithromycin erythromycin ketoconazole) 3 History of any bowel surgery except appendectomy and cholecystectomy

Design outcomes

Primary

Measure	Time frame
Defecation urgency. Timepoint: Beginning of the study and 2 months later. Method of measurement: checklist; irritable bowel syndrome severity score questionnaire.;Pain. Timepoint: Beginning of the study and 2 months later. Method of measurement: checklist; irritable bowel syndrome severity score questionnaire.;Bloating. Timepoint: Beginning of the study and 2 months later. Method of measurement: checklist; irritable bowel syndrome severity score questionnaire.;Diarrhea. Timepoint: Beginning of the study and 2 months later. Method of measurement: Bristol stool scale form; checklist; irritable bowel syndrome severity score questionnaire.	—

Measure

Time frame

Defecation urgency. Timepoint: Beginning of the study and 2 months later. Method of measurement: checklist; irritable bowel syndrome severity score questionnaire.;Pain. Timepoint: Beginning of the study and 2 months later. Method of measurement: checklist; irritable bowel syndrome severity score questionnaire.;Bloating. Timepoint: Beginning of the study and 2 months later. Method of measurement: checklist; irritable bowel syndrome severity score questionnaire.;Diarrhea. Timepoint: Beginning of the study and 2 months later. Method of measurement: Bristol stool scale form; checklist; irritable bowel syndrome severity score questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSattar Jafari

Zanjan University of Medical Sciences

jafari1354@zums.ac.ir+98 24 3377 0801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026